LCN2

October 28, 2024 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today announced that it has entered into a global distribution partnership with Beckman Coulter, Inc., a global clinical diagnostics leader. Beckman Coulter will distribute BioPorto’s neutrophil gelatinase-associated lipocalin (NGAL) tests for use on Beckman Coulter family of DxC and AU clinical chemistry analyzers. Per the agreement, Beckman Coulter will initially distribute BioPorto’s NGAL test in Europe followed by distribution in the United States pending US Food and Drug Administration (FDA) marketing clearance for ProNephro AKI (NGAL) for use on the Beckman Coulter’s analyzers. The agreement allows for expansion into other geographic areas. Kathleen Orland, Senior Vice President and General Manager, Clinical Chemistry and Immunoassay, of Beckman Coulter, commented: “We are excited by this new partnership with BioPorto on AKI assays underscoring the clinical importance and demand of NGAL as a biomarker. We look forward to now being able to offer BioPorto’s NGAL assay on our global installed base to improve kidney health management worldwide.” The agreement with Beckman Coulter is a significant milestone in the execution of BioPorto’s strategy implemented earlier in 2024 and the Company’s goal to expand its global distribution network for ProNephro AKI (NGAL) and the NGAL Test™ by partnering with leading clinical chemistry instrument manufacturers. Ultimately, this joint commitment will enable more laboratories to rapidly implement the test and increase the serviceable market. Peter Mørch Eriksen, Group CEO of BioPorto, commented: "Entering into this agreement with Beckman Coulter represents a significant milestone in our partnership portfolio. Beckman Coulter is renowned for its innovative instruments and its ability to seamlessly integrate partner assays and technologies into its analyzer family. At BioPorto, our mission is to empower healthcare professionals to address the substantial unmet medical needs of patients at risk of AKI. By expanding our distribution network, enhancing the portfolio of instruments capable of running our tests and securing collaborations with leading global manufacturers, we are well-positioned to accelerate the adoption of our AKI assessment tests. This partnership with Beckman Coulter underscores the compelling value of our technology and our commitment to improving patient outcomes.” The content of this announcement does not affect BioPorto’s latest financial guidance for 2024 as most recently described in its Interim Report for second quarter 2024. This announcement has been prepared in English and Danish. In case of discrepancy, the English version shall prevail. To receive BioPorto’s Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on https://bioporto.com/investor-contact/. For inquiries, please contact Tim Eriksen, Zenith Advisory, +45 4529 0000, investor@bioporto.com Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577, arr@lifesciadvisors.com Acute kidney injury is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in blood and makes it difficult for kidneys to maintain the proper balance of bodily fluids. AKI can also affect other organs such as the brain, heart, and lungs and is common in patients who are in hospital intensive care units. For more information about AKI please visit: https://bioporto.com/aki/. BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide. BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com. Beckman Coulter, Inc., is a global clinical diagnostics leader. To learn more about Beckman Coulter, Inc., please visit: https://www.beckmancoulter.com/. The content above comes from the network. if any infringement, please contact us to modify.

October 29, 2024Announcement no. 20 First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital COPENHAGEN, Denmark and BOSTON, MA, USA, October 29, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI) today announced the enrollment of the first patient in its US clinical study for ProNephro AKI (NGAL)™ with the goal of determining a cut-off point for risk stratification of moderate to severe of AKI in adult patients. BioPorto's ProNephro AKI (NGAL), currently cleared by the US Food and Drug Administration (FDA) for those 3 months through 21 years of age, has been widely recognized for its groundbreaking potential in refining AKI diagnosis. NGAL is a direct real-time marker of kidney cell damage and can potentially detect AKI days earlier than previously possible. Early detection of AKI may enable prompt intervention to save lives. BioPorto’s proprietary assay is a kidney injury marker versus the traditionally used serum creatinine (SCr) functional test. The cut-off study is the first of two studies which will form a substantial part of the submission for US clearance of ProNephro AKI (NGAL) in adult patients. Peter Mørch Eriksen, Group CEO of BioPorto, commented: “With strong interest from participating clinics and hospitals, forceful dedication from our team and leveraging our experience from the pediatric clearance process successfully concluded in 2023, we have progressed from a draft protocol to now enrolling the first patients at Massachusetts General Hospital, MA (US) in a very short time. I am very encouraged by the momentum we have kept, which has allowed us to speed up and commence enrollment ahead of our original plans. Accelerating the clinical process and obtaining FDA clearance for the adult test will be a very important milestone in providing clinicians this new important tool for assessing risk for clinically significant AKI, and opening up a global market valued at more than USD 3 billion annually.” The cut-off study seeks to enroll patients at up to 12 US sites in 2024 and 2025. After having established the cut-off, BioPorto expects to commence enrollment for the second study, the validation study, enabling the Company to submit its FDA application for adult usage of ProNephro AKI (NGAL) by 2026. The content of this announcement does not change BioPorto guidance for 2024, as most recently described in its Interim Report for the second quarter of 2024. This announcement has been prepared in English and Danish. In case of discrepancy, the English version shall prevail. To receive BioPorto’s Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on https://bioporto.com/investor-contact/. For inquiries, please contact Investor Relations Tim Eriksen, Investor Relations, BioPorto, +45 4529 0000, investor@bioporto.com Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577, arr@lifesciadvisors.com About Acute Kidney InjuryAcute kidney injury is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in blood and makes it difficult for kidneys to maintain the proper balance of bodily fluids. AKI can also affect other organs such as the brain, heart, and lungs and is common in patients who are in hospital intensive care units. For more information about AKI please visit: https://bioporto.com/aki/. About BioPortoBioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide. BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com. Forward-looking StatementsThis announcement may contain certain forward-looking statements. Words such as “initiate”, “may”, “focus”, “design”, “guide”, “plan”, “estimate”, “expand”, “target”, “potentially”, “will”, “should” and similar expressions identify such forward-looking statements, and such forward looking statements include statements with respect to commercialization activities in the U.S. and elsewhere, our collaboration with strategic partners, our ability to obtain regulatory approval to expand indications to analyzers other than the cobas c 501 or to other age groups and/or clinical indications, the buildout of our commercialization team and our financial guidance. Forward-looking statements involve risks, uncertainties and other factors, which may cause actual results, performance and achievements to differ materially from those contained in the forward-looking statements. These include numerous assumptions, risks and uncertainties, many of which are beyond BioPorto’s control. These assumptions, risks and uncertainties are described from time to time in BioPorto’s public announcements, its Interim Reports, and in its 2023 Annual Report under Risk Factors. BioPorto undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date of this presentation, except as required by applicable law. Attachment 2024 10 29 - Announcement no. 20 - US

October 23, 2024 News Release BioPorto Presenting FDA-cleared ProNephro AKI (NGAL) at ASN Kidney Week 2024 Conference COPENHAGEN, Denmark and BOSTON, MA, USA, October 23, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that they will participate in the upcoming American Society of Nephrology (ASN) Kidney Week 2024. The Kidney Week 2024 Annual Meeting will take place October 24-27, 2024, in San Diego, CA, USA. Kidney Week 2024 is the first ASN Conference after BioPorto received US Food and Drug Administration (FDA) clearance for the ProNephro AKI™ (NGAL) test for risk stratification of Acute Kidney Injury (AKI) in patients 3 months through 21 years of age. Jennifer Zonderman, Senior Vice President of Global Marketing at BioPorto, says: “We have been looking forward to coming back to ASN – this time with a cleared test. The opportunity to engage in discussions with leading nephrologists and industry stakeholders and elaborate on how the clinical proof we have obtained will contribute to changing the paradigm on diagnosing AKI more rapidly than what current standard-of-care allows is of tremendous importance.” The NGAL biomarker is an early marker of kidney cell damage and can potentially detect AKI days earlier than the current standard of care (serum creatinine). On Friday, October 25 th , at 10:30 AM PT (Convention Center Room 33), Prasad Devarajan, MD, FAAP, FASN (Cincinnati Children’s and BioPorto Sr. Medical Director) and David Selewski, MD, MS (MUSC Assoc. Professor) are presenting at a session highlighting the new tools available for diagnosis, risk stratification, and treatment of AKI in neonatal and pediatric patients. As Prasad Devarajan explains, “I am excited to share my experiences with NGAL at the 2024 ASN Kidney Week Conference. A low NGAL value allows for aggressive intervention in critically ill children with fluids, diuretics, and nephrotoxic medications with very low risk of AKI progression. Elevated NGAL values can trigger nephrology consultations and interventions 2-3 days earlier, providing physicians with an expanded window for clinical intervention.” In addition, following the appointment of a CRO and the national Principal Investigator, Dr. Andrew Allegretti for its upcoming US Adult clinical trials for risk stratification of severe AKI in adult populations, BioPorto will host a private meeting for the Primary Investigators (PI). Attendees will discuss the study and, in addition to Jennifer Zonderman, meet BioPorto’s Director of Clinical Affairs, Ute Feger, PhD, and its VP Global Medical Affairs, Tabari Baker, PhD. The exhibit hall will feature 40+ posters on the latest research involving kidney damage biomarkers, including NGAL. BioPorto’s commercial team will be available at booth 1737 to answer questions about ProNephro AKI and the NGAL biomarker and to schedule meetings with BioPorto’s Medical Affairs Team. To subscribe to investor news from BioPorto, please sign up at For product information visit bioporto.com or connect with a team member at For further information Jennifer Zonderman, BioPorto, +1 617 694 2918, jmz@bioporto.com Tim Eriksen, +45 4529 0000, investor@bioporto.com Ashley Robertson, LifeSci Advisors, +1 617 430 7577, arr@lifesciadvisors.com About Acute Kidney Injury Acute kidney injury is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in blood and makes it difficult for kidneys to maintain the proper balance of bodily fluids. AKI can also affect other organs such as the brain, heart, and lungs and is common in patients who are in hospital intensive care units. For more information about AKI please visit: . About BioPorto BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels which rise in relation to kidney injury, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide. BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit .